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Cyclosporine A (CsA), a widely used immunosuppressive 
drug, exerts nephrotoxic activities, as demonstrated by 
increased tubulointerstitial fibrosis, inflammation and 
podocyte damage. Recently, a number of microRNAs ex-
pressed in the kidney have been reported to be elevated 
during renal damage. Our aim was to investigate the ef-
fect of CsA on selected microRNAs in the mouse kidney 
after CsA treatment. Moreover, as heme oxygenase-1 
(HO-1, encoded by the Hmox1 gene) was shown to play 
a protective role during kidney disorders, we assessed 
whether HO-1 deficiency in vivo influences the CsA-regu-
lated microRNAs’ expression. We have observed that the 
pro-fibrotic miR-21 and pro-apoptotic miR-34a expres-
sion was upregulated in kidneys of HO-1 deficient mice 
and it was further enhanced by CsA. Concomitantly, the 
level of anti-fibrotic microRNAs, belonging to miR-29 and 
miR-200 families, was down-regulated after CsA treat-
ment. Generally, Hmox1 knock-out (Hmox1–/–) animals 
were more susceptible to CsA treatment, as the mortality 
rate was 4 out of 9 Hmox1–/– mice, and increased fibrosis 
(Tgfb2, Pai1), inflammation (Il6) and apoptosis (Cdkn1a-
p21) were noticed in the HO-1 deficient kidneys. In sum-
mary, our data demonstrate that CsA induces significant 
changes in the expression of renal microRNAs and em-
phasize HO-1 deficiency as an important factor contrib-
uting to the CsA-mediated renal toxicity.
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INTRODUCTION
Cyclosporine A (CsA), a calcineurin inhibitor, is one 
of the most effective and widely used immunosup-
pressants in solid organ transplantation and autoim-
mune diseases; however, it exerts strong nephrotoxic 
effects. Inflammation, apoptosis, and fibrosis associated 
with oxidative stress play a pivotal role in producing 
structural and functional kidney impairment in CsA-
induced renal injury (Bennett et al., 1996; Camilleri et 
al., 2016; Naesens et al., 2009). Recently, modulation of 
microRNAs’ expression has been suggested as a pos-
sible new mechanism of action of nephrotoxic agents. 
Previously, we have observed increased expression of 
miR-21 and miR-34a in the mouse kidney after ochra-
toxin A (OTA) stimulation, a factor with known nephro-
toxic activity (Loboda et al., 2017a; Loboda et al., 2017b). 
The role of microRNAs in CsA nephrotoxicity has been 
also evaluated in other recent studies showing, among 
others, up-regulation of pro-fibrotic miR-21 both, in vitro 
(Chen et al., 2015) and in vivo (Gooch et al., 2017).
Heme oxygenase-1 (HO-1, encoded by the Hmox1 
gene) not only catalyzes conversion of heme to biliver-
din, carbon monoxide and iron ions, but it also exerts 
anti-inflammatory, anti-apoptotic and anti-oxidant prop-
erties (Loboda et al., 2016a). The level of HO-1 ex-
pression in human population can vary because of the 
known HMOX1 promoter polymorphism – the number 
of guanosine thymidine dinucleotide (GT)n repeats in the 
promoter region is inversely associated with HMOX1 
mRNA expression and HO enzyme activity (Loboda 
et al., 2008; Taha et al., 2010). Importantly, HO-1 was 
shown to play a pivotal role in the kidney protection 
against harmful insults in several models of kidney dis-
orders, including unilateral ureteral obstruction (UUO) 
(Correa-Costa et al., 2010), diabetic induced-glomerular 
injury (Elmarakby et al., 2012) and transplant rejection 
(Li et al., 2011). We have already demonstrated that 
HO-1 protects against OTA-induced nephrotoxicity, as 
lack of HO-1 increased inflammation, apoptosis and fi-
brosis, whereas its induction with cobalt protoporphyrin 
(CoPPIX) halted OTA toxicity (Loboda et al., 2017a).
The importance of HO-1 in CsA-induced kidney fail-
ure was already suggested (Shin et al., 2010); however, 
the involvement of microRNAs in such a process has 
not been evaluated until now. However, we have pre-
viously found that HO-1 is a regulator of microRNAs 
expression and biogenesis in satellite cells (Kozakowska 
et al., 2012), it controls miR-206-dependent myogenic 
program in rhabdomyosarcoma (Ciesla et al., 2016) and 
modulates miR-378 effect in human non-small cell lung 
carcinoma (NSCLC) development (Skrzypek et al., 2013). 
More importantly, there is a cross-talk between HO-1 
and microRNAs in the kidney cells (Stachurska et al., 
2013).
As HO-1 may regulate the expression of microRNAs 
and it may exert protective effect against CsA-induced 
kidney damage, we aimed to investigate a possible in-
volvement of microRNAs in CsA toxicity. We used 
Hmox1 knock-out mice in order to elucidate the role 
of HO-1 in the observed effects. For our study, we 
decided to use a relatively low dose of CsA (15 mg/
kg/bw), based on the literature data and the fact that 
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Hmox1 knock-out animals are generally more sensitive 
to various stressors. According to the work by Yadav et 
al., daily intraperitoneal injection of CsA (15 mg/kg/day 
for 30 days) caused renal dysfunction in Tmbim6 knock-
out mice (Yadav et al., 2015). In another study, various 
concentrations of CsA (7.5–30 mg/kg/day injected i.p 
for 4 weeks) were used and already the lowest dose was 
able to exert a profibrotic effect (Lim et al., 2012). In 
conclusion, we have demonstrated that microRNAs af-
fecting such processes as fibrosis and apoptosis might be 
regulated by CsA and, of importance, the effect of im-
munosuppressant is accelerated in HO-1 deficient mice.
MATERIALS AND METHODS
Ethics statement. All animal experiments were per-
formed in accordance with the national and European 
regulations upon approval by the First Local Ethical 
Committee on Animal Testing at the Jagiellonian Uni-
versity in Krakow. Animals were maintained under a 
constant 12 h dark/light cycle at the environmental tem-
perature of 22 ± 2°C, and were provided with normal 
laboratory pellet diet and water ad libitum.
Animals. Experiments were performed on 
C57BL/6 × FVB mice with normal level of Hmox1 
(Hmox1+/+) and on littermate mice lacking both Hmox1 
alleles (Hmox1−/−), of both sexes. The mice were gener-
ated from the Hmox1+/− breeding pairs kindly gifted by 
Dr. Anupam Agarwal (Birmingham, AL, USA). Animals 
were genotyped three weeks after birth by PCR using tail 
DNA, as described previously (Poss & Tonegawa, 1997).
Experimental procedure. 6-month-old mice fed a 
low salt diet (Na+ 0.02%) were injected every other day 
for 19 days intraperitoneally (i.p.) with 15 mg/kg bw 
CsA dissolved in ethanol and diluted in olive oil, pro-
ducing a working solution (10 mg/ml). As a control, ol-
ive oil with ethanol (10%) was used. On the last day of 
experiment, the mice were sacrificed and blood and kid-
neys were taken for the downstream analysis.
Analysis of renal and liver markers. Serum level of 
creatinine, blood urea nitrogen (BUN), alanine aminotrans-
ferase (ALAT) and aspartate aminotransferase (ASPAT) were 
determined in blood by using a standard commercial kit 
(Spotchem Arkray) according to the manufacturer’s in-
structions with the Spotchem EZ SP-4430 analyzer.
Reverse Transcription and quantitative real-
time PCR. Total RNA was isolated by using a modi-
fied Chomczynski and Sacchi protocol (Chomczynski 
and Sacchi, 1987). Kidney fragments were homoge-
nized in 1 ml of QIAzol Total RNA Isolation Reagent 
by using a TissueLyser (Qiagen). Then, samples were 
subjected to chloroform extraction and isopropanol 
precipitation. RNA pellets were dissolved in nuclease-
free water and subsequently RNA concentration and 
purity were determined spectrophotometrically by us-
ing NanoDrop 1000 (Thermo Fisher Scientific). Re-
vertAid Reverse Transcriptase (Thermo Fisher Scien-
tific) or NCodeTM VILOTM miRNA cDNA Synthesis 
Kit (Invitrogen) were used for reverse transcription, 
as described earlier (Stachurska et al., 2013). Quantita-
tive real-time PCR was done with the use of SYBR 
Green PCR Master Mix (Sigma-Aldrich), specific re-
verse and forward primers, and 30 ng of cDNA, uti-
lizing StepOnePlus™ Real-Time PCR System (Applied 
Biosystems). Eef2 (encoding eukaryotic translation 
elongation factor 2, EF-2) and U6 snRNA were used 
to normalize the expression of examined mRNAs and 
microRNAs, respectively.
Preparation of the tissue lysates. Fragments of kid-
ney isolated from each animal were homogenized by 
using an automatic Tissue Lyser (Qiagen) in ice-cold 
PBS containing 1% Triton X-100 and protease inhib-
itors (1 μg/ml phenylmethylsulfonyl fluoride, 1 μg/
ml leupeptin, and 1 μg/ml aprotinin). Then, the sam-
ples were incubated for 30 min on ice and centrifuged 
(12 000 × g, 10 min, 4°C). Clear supernatants were col-
lected and total protein concentration was determined by 
the bicinchoninic acid protein assay kit (Sigma-Aldrich), 
according to the vendor’s protocol. Kidney lysates were 
subjected to luminex analysis, ELISA and/or Western 
blotting analysis.
Luminex analysis. Kidney lysates, as well as mouse 
serum, were used for determination of the cytokine con-
tent using multiplex Luminex technology. The concen-
tration of interleukin (IL)-6 and plasminogen activator 
inhibitor-1 (PAI-1) was measured according to the man-
ufacturer’s instructions (Millipore, Billerica, MA, USA). 
Data were analyzed by using a Flexmap 3D instrument 
and Luminex xPONENT® 4.0 Software and Luminex 
Analyst Program (Luminex Corporation, Austin, Texas, 
USA).
Western blotting. Western blotting was performed 
as described previously (Mucha et al., 2018). Mem-
branes were probed with primary antibodies against 
HO-1 (ADI-SPA-894, Enzo Life Sciences) and α-tubulin 
(CP06, Calbiochem), overnight at 4°C. Antibodies were 
diluted in a blocking buffer (0.1% Tween20 in TBS with 
5% nonfat dry milk). HRP activity was detected using 
Immobilon Western Chemiluminescent HRP Substrate 
(WBKLS0500 EMD Millipore).
ELISA for HO-1. HO-1 protein quantification in the 
kidney lysates was performed by using a Mouse Heme 
Oxygenase 1 ELISA Kit (ab204524, Abcam) according 
to the manufacturer’s instructions.
Masson’s trichrome staining. Paraffin-embedded 
kidney sections (6 μm) were sliced, deparaffinized and 
rehydrated. Kidney fibrosis was assessed with the Mas-
son’s trichrome stain (Sigma-Aldrich). Results were ob-
served under light microscopy. Evaluation of fibrosis 
was performed by a person that was blind to the mice 
genotype and treatment, using the following assessment 
– 0 – no signs of collagen deposition; 1 – any sign of 
collagen deposition; 2 – clearly visible collagen deposi-
tion; 3 – collagen deposition on half of field of view; 4 
– fibrosis took up more than half of field of view.
Statistical analysis. Data are presented as mean ± 
standard error (SEM). Statistical assessment was done by 
analysis of variance (ANOVA), followed by a Bonferroni 
post-hoc test for multiple comparisons, or with Student’s 
t-test for two group comparisons. Differences were ac-
cepted as statistically significant at p<0.05.
RESULTS
CsA exerts nephrotoxic effects in HO-1 deficient mice
At first, we confirmed our animal model (HO-1 defi-
cient mice) by assessing the expression of HO-1 and we 
investigated the effect of CsA treatment on HO-1 ex-
pression in the kidneys of wild type animals. We were 
not able to detect HO-1 in Hmox1 knock-out animals 
(not shown) and we did not observe any effect of CsA 
treatment on HO-1 expression in WT mice (Fig. 1A–C).
Importantly, we have demonstrated that Hmox1 
knock-out mice were more susceptible to CsA toxicity. 
Accordingly, CsA treatment (15 mg/kg bw delivered 
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Figure 1. HO-1 expression is not regulated by CsA in wild type animals but Hmox1 knock-out (Hmox1–/–) mice are more susceptible 
to CsA toxicity.
Hmox1 mRNA expression assessed by real-time PCR (A), protein level assessed by ELISA (B) and western blot (C) in the mouse kidneys 
is not regulated by CsA in wild-type animals. After CsA treatment, 4 out of 9 Hmox1–/– mice had died, whereas in wild-type animals no 
mortality was observed (D). The biggest decrease in body weight was found in the Hmox1 knock-out animals after CsA treatment (E). The 
markers of renal function, blood urea nitrogen (F) and creatinine level (G) were upregulated in mice of both genotypes, whereas total 
protein level (H) was increased only in the Hmox1–/– mice treated with CsA. Mean of 5–9 animals/group, *p<0.05 vs. control.
Figure 2. Increased kidney fibrosis is observed in Hmox1 knock-out animals
Increased collagen deposition (assessed by Masson’s trichrome staining) was observed in kidneys of Hmox1 knock-out animals as 
indicated by the photos (A) and quantification of the staining (B). The difference in kidney weight was also prominent in the Hmox1 
knock-out animals (C). Mean of 5–9 animals/group, #p<0.05 vs. Hmox1+/+ control animals, $p<0.05 vs. Hmox1+/+ CsA-treated mice.
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intraperitoneally every other day for 19 days) resulted 
in death of 4 out of 9 Hmox1–/– mice (~44% mortality) 
(Fig. 1D). Moreover, CsA caused the highest decrease in 
the total body weight in HO-1 deficient mice (Fig. 1E). 
The levels of kidney function markers, namely BUN 
(Fig. 1F) and creatinine (Fig. 1G) were up-regulated in 
the mouse serum of both, the Hmox1+/+ and Hmox1–
/– mice, whereas the total protein level (Fig. 1H) was 
increased in a statistically significant way only in the 
Hmox1 knock-out animals treated with CsA. In contrast, 
markers of the liver injury (ALAT and ASPAT) were not 
changed (data not shown).
Markers of fibrosis, inflammation and apoptosis are 
elevated after CsA treatment mostly in mice lacking 
HO-1
CsA treatment may lead to fibrosis, inflammation 
and apoptosis (1). In our experimental model, fibrosis 
(collagen deposition) assessed by Trichrome staining 
(Fig. 2A, B) was mostly affected by lack of HO-
1. Also, the kidney weight was increased in Hmox1 
knock-out animals (Fig. 2C), but was not influenced 
by CsA treatment. However, a more detailed molecular 
analysis indicated elevated expression of pro-fibrotic 
transforming growth factor-β2 (Tgfb2) in the Hmox1-
/- animals (Fig. 3A), whereas no statistically significant 
difference in the expression of Tgfb1 after CsA treatment 
was observed (not shown). On the other hand, the 
level of anti-fibrotic Bmp7 was decreased irrespectively 
of the mice genotype (Fig. 3B). Expression of Cdkn1a 
(p21), a p53-inducible gene (Georgakilas et al., 2017) was 
significantly increased by CsA in HO-1 deficient mice 
(Fig. 3C). Similarly, Il6 mRNA expression (Fig. 3D) and 
IL-6 protein synthesis (Fig. 3E) were increased mostly in 
the Hmox1-/- mice. Interestingly, in the mouse serum, a 
higher level of plasminogen activator inhibitor-1 (PAI-1) 
induced by CsA was detected (Fig. 3F), independently of 
HO-1 presence.
CsA regulates expression of microRNAs in an HO-1 
dependent manner
Based on the importance of some microRNAs in the 
kidney pathophysiology and on our previous studies with 
nephrotoxic agent, OTA (Loboda et al., 2017b; Loboda 
et al., 2016b; Metzinger-Le Meuth et al., 2018), we 
have assessed if CsA modulates expression of selected 
microRNAs in the mouse kidney and if the HO-1 
level has any impact on such regulation. As indicated 
in Fig. 4A, B, the level of anti-fibrotic microRNAs, 
namely miR-29b and miR-200c, was slightly decreased 
Figure 3. CsA treatment influences the expression of fibrotic, apoptotic and inflammatory markers in the kidneys of Hmox1+/+ and 
Hmox1–/– mice.
Pro-fibrotic Tgfb2 (A), anti-fibrotic Bmp7 (B), pro-apoptotic Cdkn1a (C) and pro-inflammatory Il6 (D) transcript levels (normalized to Eef2) 
were assessed using qRT-PCR. Protein level of IL-6 (E) and PAI-1 (F) was checked by luminex in the mouse serum. Data are presented as 
a fold change over control Hmox1+/+ mice. Mean of 5–9 animals/group, *p<0.05 vs. control in each genotype, #p<0.05 vs. Hmox1+/+ control 
animals.
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by CsA in WT animals, but the effect was greater (and 
statistically significant) in mice lacking HO-1. Moreover, 
the expression of pro-fibrotic miR-21 and pro-apoptotic 
miR-34a was increased in the kidneys of Hmox1–/– 
mice in comparison to WT counterparts. Notably, CsA 
treatment further increased their level only in the Hmox1 
knock-out animals (Fig. 4C, D).
DISCUSSION
Cyclosporine A (CsA)-induced glomerulosclerosis and 
tubulointerstitial fibrosis is a well-described side effect of 
CsA treatment that limits its long-term use (Bennett et 
al., 1996). The mechanisms of CsA toxicity have been 
investigated for the past several years and new possible 
factors implicated in its nephrotoxic effect have been 
demonstrated (Camilleri et al., 2016; Naesens et al., 2009). 
The aim of our study was to evaluate the involvement of 
HO-1 in the effects triggered by CsA in mice. Moreover, 
we have studied contribution of small non-coding RNA 
molecules – microRNAs in CsA-induced nephrotoxicity.
We and others have reported that an elevated level 
of HO-1 exerts protective effects under various stressful 
conditions (reviewed in: Loboda et al., 2016a; Loboda 
et al., 2008) and previous studies have shown induction 
of HO-1 after CsA treatment, both in vitro in the rat 
tubular epithelial NRK-52E cells (Shin et al., 2010) 
and in vivo in the rat kidney (Capasso et al., 2008). In 
our hands, no differences in the HO-1 level upon 
CsA treatment were detected, possibly because of the 
different experimental scheme with a relatively low dose 
of CsA used. Nonetheless, as shown by us, the lack of 
HO-1 causes accumulation of collagen and increased 
kidney weight (kidney hypertrophy). Moreover, HO-1 
deficiency promoted expression of miR-21 and miR-
34a, the markers of fibrosis and apoptosis, indicating 
the importance of this protective enzyme in the kidney 
homeostasis. Such regulation was also observed by us 
previously in other experimental settings in the mouse 
kidney (Loboda et al., 2017a) and in fibroblasts isolated 
from the Hmox1 knock-out mice (Stepniewski et al., 
2018). Through its anti-apoptotic, anti-inflammatory and 
anti-oxidant properties, HO-1 may also protect against 
toxic insults as the extent of fibrosis was accelerated in 
the HO-1 knock-out animals treated with OTA (Loboda 
et al., 2017a; Stachurska et al., 2013).
Interestingly, we have identified several microRNAs 
that are regulated in the kidneys exposed to OTA, but 
this effect was HO-1-independent (Loboda et al., 2017a). 
In contrast, as shown in the study presented here, the 
differences in the expression of pro-fibrotic miR-21, 
anti-fibrotic miR-29b and miR-200b, as well as pro-ap-
optotic miR-34a, were aggravated by the lack of HO-1 
in the CsA-induced nephrotoxicity. Notably, miR-21 was 
previously found to mediate CsA nephrotoxicity via the 
PTEN/AKT signaling pathway in the human proximal 
tubular epithelial cells (HPTECs) (Chen et al., 2015). 
Recent study by Gooch et al. revealed 76 differentially 
expressed microRNAs in kidneys of mice that received 
CsA (20 mg/kg) or vehicle treatment daily for six weeks 
(Gooch et al., 2017). Except changes in particular mi-
croRNAs which were previously linked to renal fibrosis, 
like let-7d, miR-21, miR-29, miR-30, miR-130, miR-192, 
and miR-200a, microRNAs that have not been reported 
to be related to nephrotoxicity or immunosuppression 
(such as miR-186 and miR-709) were also found to be 
dysregulated (Gooch et al., 2017). Interestingly, we did 
not observe induction of miR-21 in the wild type ani-
mals. However, even upon more frequent and longer ad-
ministration of CsA applied by Gooch et al., induction 
Figure 4. CsA treatment influences expression of microRNAs in the mouse kidneys in an HO-1 dependent way.
Expression of anti-fibrotic miR-29b (A) and miR-200b (B) is decreased in Hmox1 knock-out animals treated with CsA. Expression of major 
pro-fibrotic microRNAs, miR-21 (C) and miR-34a (D) is increased by HO-1 deficiency and is further up-regulated by CsA. Transcript levels 
were normalized to snU6 and is shown as a fold of change over control Hmox1+/+ mice. Mean of 5-9 animals/group, *p<0.05 vs. control in 
each genotype, #p<0.05 vs. Hmox1+/+ control animals.
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of miR-21 in healthy wild type mice was rather moderate 
(less than 2 fold induction was measured by quantita-
tive real-time PCR analysis and 2.19 fold induction by 
RNA sequencing). miR-21 was suggested to be a univer-
sal biomarker of kidney pathology and was found to be 
increased in response to various stimuli, not only in this 
organ but also in the serum, plasma, and urine (reviewed 
in: Loboda et al., 2016b). Thus, it would be of interest to 
further extend our analysis beyond the kidney to verify 
its utility as a biomarker in our experimental scheme.
In our study, we also observed an increased expres-
sion of miR-34a, regulated by the p53 signaling pathway, 
in the CsA-treated HO-1 knock-out mice. DNA damage 
and cell cycle arrest accompanied with elevated p53 level 
are found to be early events in the CsA nephrotoxicity, 
both in vitro (Lally et al., 1999) and in vivo (Shihab et al., 
1999). We did not assess expression of p53 or p21 regu-
lator in this study, but we have shown previously that 
treatment the with another nephrotoxic agent, OTA, 
leads to a significant and concomitant upregulation of 
miR-34a, p53, p21 and p53 upregulated modulator of 
apoptosis (PUMA) expression (Loboda et al., 2017a). In-
creased apoptosis, including p21 induction, was already 
observed in the renal proximal tubular cells in vitro after 
CsA stimulation (Jennings et al., 2007).
In addition, Yuan et al. pointed out to miR-494 as re-
sponsible for CsA-induced nephrotoxicity and epithelial 
to mesenchymal transition (EMT) progression (Yuan et 
al., 2015). Finally, Sun  and coworkers (Sun et al., 2017) 
identified miR-181c as a factor protecting renal tissues 
from CsA-induced nephrotoxicity.
Our results indicate that selected microRNAs, which 
were known to be altered in the diseased kidneys, are 
regulated by CsA in an HO-1-dependent way. It would 
be also interesting to study if CsA may influence the to-
tal pool of microRNAs, as well as the expression of mi-
croRNAs processing enzymes. In microRNAs biogenesis, 
DiGeorge syndrome critical region gene 8, (DGCR8), a 
heme-dependent protein, plays a critical role in the first 
step of primary microRNAs (pri-miRNAs) processing 
(Faller et al., 2007). In our previous study, DGCR8 was 
shown to be decreased by HO-1 overexpression (Koza-
kowska et al., 2012), whereas its level was upregulated in 
porcine renal epithelial cells stimulated by OTA, which 
concomitantly inhibited HO-1 expression (Stachurska 
et al., 2013). Therefore, it might be suggested that the 
DGCR8 level, as well as its properties, depend on the 
HO-1 activity.
HO-1 is a well-known anti-inflammatory factor (Lo-
boda et al., 2016a, 2008). In the study presented here, ex-
pression of IL-6, a marker of inflammation, was induced 
by CsA at the mRNA level in the kidneys and at the 
protein level in the serum only in the Hmox1-/-animals, 
suggesting that the lack of HO-1 triggers an inflamma-
tory reaction after CsA treatment. Similarly, Cdkn1a (p21) 
expression was elevated only in the HO-1 deficient kid-
neys.
PAI-1, not expressed in the kidneys under normal 
conditions, is rapidly induced in a wide variety of acute 
and chronic renal diseases. Accordingly, PAI-1 was 
shown to be implicated in glomerulosclerosis and tubu-
lointerstitial fibrosis (reviewed in: (Eddy, 2009). Moreo-
ver, CsA-induced up-regulation of PAI-1 was observed 
in vitro in the rat mesangial cells (Waiser et al., 2002) 
or in vivo in the rat kidney (Pereira et al., 2006). Here, 
we report that in Hmox1 knock-out animals, the rate 
of induction of Pai1 expression after CsA is more pro-
nounced than in wild-type mice (69% vs 34% induction, 
p=0.0098). Concomitantly, increased collagen deposition 
and expression of Tgfb2 demonstrates pro-fibrotic chang-
es in the kidneys of HO-1 deficient mice subjected to 
CsA treatment.
Lack or only mild changes in the expression of ex-
amined genes in control mice after CsA treatment may 
suggest that our scheme of the experiment, including 
the chosen dose of CsA, was too gentle to cause potent 
fibrotic, inflammatory or apoptotic effects; however, it 
was sufficient to trigger such a response in mice lacking 
HO-1.We have also observed mortality in Hmox1 knock-
out animals after CsA injections, which might indicate 
(but not prove) an increased sensitivity to nephrotoxic 
insults. Hence, HO-1 seems to play a protective role 
against CsA-mediated toxicity in wild-type animals.
Altogether, our data indicate a higher renal damage in 
animals lacking HO-1. Based on these results, it might 
be proposed that in HO-1 deficient mice the disruption 
of kidney architecture might be related to disturbances 
in extracellular matrix synthesis and increased apoptosis 
and inflammation, which collectively can be considered 
as major mechanisms of CsA toxicity. As highlighted in 
this study, specific microRNAs are also implicated in this 
process.
It has to be emphasized that our results indicate an 
increased sensitivity of Hmox1 knock-out animals to 
CsA treatment, however, in the human population, in-
stead of total HO-1 deficiency, a rather decreased level 
of HMOX1 mRNA expression and HO enzyme activity 
might be detected in people with longer (GT)n repeats in 
the HMOX1 promoter (Loboda et al., 2008; Taha et al., 
2010). Thus, HO-1 heterozygous mice potentially could 
be used to recapitulate, at least partially, the situation ob-
served in the human population. Nevertheless, one may 
speculate that CsA toxicity and its influence on micro-
RNAs’ expression might be patient-specific. However, 
such data are not available so far.
Our results may also help to understand some molecu-
lar aspects of CsA-related toxicity after heart transplanta-
tions. Triple therapy based on calcineurin inhibitors (CsA 
or tacrolimus), antiproliferative agents (azathioprine or 
mycophenolate mofetil) and steroids, can be used as the 
gold standard immunosuppressive therapy after cardiac 
transplantation (Guethoff et al., 2013; O’Neill et al., 2004). 
CsA monotherapy has been also tested and its effective-
ness was compared with the double therapy (CsA with 
azathioprine) in the long-term heart transplant recipients, 
surviving more than 5 years (Sansone et al., 2010). No dif-
ferences in the survival rate and major events, including 
heart failure, malignancy, infection and cardiac allograft 
vasculopathy (CAV), were reported, suggesting the useful-
ness of CsA treatment (Sansone et al., 2010). Nonetheless, 
data from retrospective analysis indicate that the renal fail-
ure is a frequent cause of death after heart transplantation, 
and 10 years after such operation around 6% of patients 
require dialysis and about 4% need renal transplantation 
(reviewed in: (Söderlund & Rådegran, 2015)). Those ad-
verse effects could be the result of CsA toxicity, therefore, 
minimizing the use of this immunosuppressant is suggest-
ed to decrease chronic kidney diseases after heart trans-
plantations. Recently, involvement of specific microRNAs 
in the toxic effects of CsA on cardiomyocytes has been 
also reported. Zhu  and coworkers (Zhu et al., 2016) have 
identified miR-377 as the factor responsible for cardio-
myocyte apoptosis after CsA treatment. More importantly, 
miR-21 level that was increased in the renal tissues after 
CsA treatment, as shown in our and other studies (Chen 
et al., 2015), was suggested to be a predictive marker of 
the development of acute kidney injury after cardiac sur-
gery (Gaede et al., 2016).
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In summary, we have shown that Hmox1 knock-out 
mice are more susceptible to CsA toxic effects through 
the increased fibrosis, inflammation and apoptosis, in-
cluding microRNA regulation. Therefore, the level of 
Hmox1 expression (which can vary because of the known 
HO-1 promoter polymorphism) might be an important 
factor regulating patient’s response to the CsA treatment, 
however, this requires further studies.
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